CI

Cigna is a scale health company priced like a melting ice cube but behaving like a steady cash machine. At $279.27 it trades at just 12.6x FY2025 diluted EPS of $22.18 and 0.3x its $275B revenue, with a $73.6B market cap against $9.60B of operating cash flow — a high free-cash-flow yield that, combined with a 3.7% reduction in share count and $3.62B of buybacks, is the core of the bull case. EPS jumped +83% (vs net income +73.5%), partly because the share base shrank, and retained earnings grew +10%. For a self-directed investor, the valuation alone makes this hard to dismiss: you are paying a low-teens multiple for the largest pharmacy-benefit/health platform in the US.

The quality of that earnings jump is where I temper enthusiasm. Operating income actually fell -2.3% to $9.20B even as revenue rose +11.2%, so the headline net-income surge is flattered by non-operating and prior-year-comparison effects rather than improving core economics. The MD&A shows the mix deteriorating: pharmacy revenues (Express Scripts) grew +17% to $216.7B but pharmacy/other service costs grew +18% to $215.0B — essentially pass-through, ultra-thin spread — while higher-margin Premiums fell -12% to $40.3B and medical costs fell -11%. The insured book is shrinking and growth is concentrating in the lowest-margin business. That is why operating margin sits at just 3.3% and net margin at 2.2%; this is a high-revenue, low-margin model where small pricing misses swing results hard.